Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 known ✓ | P04062 | 1/20 | 0.39 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CPN1 | P15169 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL4322353 | 1.00 | TSHR (0.40) | TSHRGBA1NFKB1CYP2C19CPN1 | |
| Cadaverine Tartrate SCHEMBL7749321 | 1.00 | TSHR (0.40) | TSHRGBA1NFKB1CYP2C19CPN1 | |
| Cadaverine Tartrate SCHEMBL7743890 | 1.00 | TSHR (0.40) | TSHRGBA1NFKB1CYP2C19CPN1 | |
| Bicarbonate SCHEMBL16669009 | 0.85 | SLC6A1 (0.37) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Acetic Acid SCHEMBL28598584 | 0.83 | SLC6A1 (0.35) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Oxalic Acid SCHEMBL9319555 | 0.83 | SLC6A1 (0.35) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Acetic Acid SCHEMBL28060470 | 0.81 | SLC6A1 (0.34) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Acetic Acid SCHEMBL28060411 | 0.81 | SLC6A1 (0.34) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Acetic Acid SCHEMBL27717590 | 0.81 | SLC6A1 (0.34) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Maleic Acid SCHEMBL27641950 | 0.78 | TSHR (0.38) | TSHRSLC6A1SLC6A11SLC6A13LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569690-B2 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1548010-A1 | PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161003-A1 | Process for producing oxycarbonyl-substituted piperazine derivative | DHPS, AQP4, OGFOD1 | GBA1 898/4885GABRA1 3757/4885SLC6A2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.